DDrare
Disease
Drug
Target Gene/Pathway
問合せ先
EN
18. 脊髄小脳変性症(多系統萎縮症を除く。)
Spinocerebellar degeneration
Clinical trials
/
Disease details
臨床試験数
:
76
/
薬物数
:
98
- (
DrugBank
:
31
) /
標的遺伝子数
:
44
-
標的パスウェイ数
:
65
Search
1 trial found
10
50
100
ALL
diseases per page:
Showing 1 to 1 of 1 diseases
Filter by
Reset
No.
TrialID
Date_
enrollment
Date_
registration
Public_title
Scientific_title
Condition
Intervention
Primary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
Phase
Countries
1
EUCTR2007-005371-34-FR
(
EUCTR
)
18/03/2008
20/12/2007
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIA
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 month ...
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study. - EGB 761 in FRIEDREICH ATAXIA
EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIAA 3 month ...
Out patient suffering from friedreich ataxia aged from 12 to 20 years
Trade Name:
Rokan (r) Novo 120 mg
Product Name:
EGB 761 (r) 120 mg
INN or Proposed INN:
Standardized
Ginkgo Biloba Extract
(EGb 761 (r)
Trade Name:
Rokan (r) Novo 120 mg
Product Name:
EGB 761 (r) 120 mg
INN or Proposed INN:
Standardized
G
...
BEAUFOUR IPSEN PHARMA
NULL
Not Recruiting
Female: yes
Male: yes
20
Phase 2
France